Pfizer
NYSE:PFEPharmaNew York, United States · Est. 1849 · 88,000 employees
Global pharmaceutical and biotechnology corporation.
72
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
88
Indications↗
Distinct diseases across all programs
3,883
Clinical Trials↗
All sponsored trials (all statuses)
91
Orange Book Patents
Across 17 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
72 drugs in development
Approved2
Phase 325
Phase 219
Phase 123
Preclinical22
By Therapeutic Area
top 6
Oncology
2831%
Immunology
1011%
Infectious Disease
78%
Respiratory
56%
Metabolic & Endocrine
44%
Hematology
44%
R&D Momentum
100/100
Pipeline Velocity
91/100
Trial Completion Rate
82/100
Pipeline Concentration
17/100
Pipeline Freshness
74/100
Strategic Signals
- ↗Active in Gastroenterology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Oct 10, 2026
Recruiting
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF TILREKIMIG IN ADULT AND ADOLESCENT PARTICIPANTS WITH SEVERE ASTHMA
Oct 10, 2026
Recruiting
A PHASE 2 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED TRANSFORMED SMALL CELL LUNG CANCER
Oct 10, 2026
Recruiting
AN INTERVENTIONAL PHASE 3 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN PARTICIPANTS 60 YEARS OF AGE AND OLDER
Oct 9, 2026
Recruiting
A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER
Oct 9, 2026
Recruiting
A PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA
Oct 9, 2026
Recruiting
AN INTERVENTIONAL OPEN-LABEL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 IN COMBINATION WITH DIFFERENT ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Oct 9, 2026
Recruiting
AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Oct 9, 2026
Recruiting
AN INTERVENTIONAL, OPEN-LABEL, PHASE 2 STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY OR IN COMBINATION IN ADULT PARTICIPANTS WITH EARLY-STAGE RESECTABLE OR LOCALLY ADVANCED UNRESECTABLE NON-SMALL CELL LUNG CANCER
Oct 9, 2026
Recruiting
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY BEROBENATIDE IN ADULTS WITH OBSTRUCTIVE SLEEP APNEA AND OVERWEIGHT OR OBESITY RECEIVING POSITIVE AIRWAY PRESSURE THERAPY (VESPER-OSA 1)
Oct 9, 2026
Recruiting
AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA
Oct 9, 2026
Recruiting
AN INTERVENTIONAL PHASE 1B/2, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, ANTITUMOR ACTIVITY, AND PHARMACOKINETICS OF PF 08634404 MONOTHERAPY OR IN COMBINATION WITH ENFORTUMAB VEDOTIN IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER
Oct 9, 2026
Recruiting
AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER
Details
Company Info
Company Overview
$160.0B
Mkt Cap
$59.6B
Revenue
$1.0B
Cash
CEOAlbert Bourla
Founded1849
Employees88,000
HQNew York, United States
ExchangeNYSE:PFE
Websitepfizer.com
LinkedInCompany Page
Therapeutic Focus
ImmunologyOncologyOtherHematologyPsychiatryCardiovascularNeurologyMetabolic & EndocrineMusculoskeletalRespiratoryNephrologyGastroenterologyInfectious DiseaseDermatologyRare DiseaseOphthalmology
Recent SEC Filings
8-KAug 4, 2026
8-K
8-KJun 18, 2026
8-K
8-KJun 18, 2026
8-K
EX-99Feb 3, 2026
PFIZER INC (PFE) (CIK 0000078003)
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular(1 drug)
—
—
1
—
—
Cardiovascular(1 drug)
Dermatology(3 drugs)
—
—
1
3
1
Dermatology(3 drugs)
Gastroenterology(2 drugs)
1
—
—
—
1
Gastroenterology(2 drugs)
Hematology(4 drugs)
2
1
1
1
—
Hematology(4 drugs)
Immunology(10 drugs)
3
1
3
3
1
Immunology(10 drugs)
Infectious Disease(7 drugs)
2
—
2
3
—
Infectious Disease(7 drugs)
Metabolic & Endocrine(4 drugs)
1
—
3
—
1
Metabolic & Endocrine(4 drugs)
Musculoskeletal(1 drug)
1
—
—
—
—
Musculoskeletal(1 drug)
Nephrology(1 drug)
—
—
—
—
1
Nephrology(1 drug)
Neurology(2 drugs)
1
—
—
1
—
Neurology(2 drugs)
Oncology(28 drugs)
5
13
6
10
—
Oncology(28 drugs)
Rare Disease(2 drugs)
—
—
—
2
—
Rare Disease(2 drugs)
Respiratory(5 drugs)
3
—
1
—
1
Respiratory(5 drugs)
Unknown / Other(20 drugs)
4
10
3
5
1
Unknown / Other(20 drugs)
Regulatory
Regulatory Timeline
20256 events
FDADec 12
Depo-Provera — DEPO-PROVERA
Application NDA020246
FDANov 21
Padcev — PADCEV
Application BLA761137
FDANov 14
Aldactone — ALDACTONE
Application NDA012151
FDANov 4
Medrol — DEPO-MEDROL
Application NDA011757
FDANov 4
Medrol — SOLU-MEDROL
Application NDA011856
FDANov 4
Medrol — MEDROL
Application NDA011153
202618 events
FDAAug 17
Zavzpret — ZAVZPRET
Application NDA216386
SECAug 4
8-K
Accession: 0000078003-26-000094
FDAJul 10
Padcev — PADCEV
Application BLA761137
FDAJun 24
Ibrance — IBRANCE
Application NDA207103
FDAJun 24
Ibrance — IBRANCE
Application NDA212436
SECJun 18
8-K
Accession: 0000078003-26-000087
SECJun 18
8-K
Accession: 0000078003-26-000085
FDAJun 9
Zyvox — ZYVOX
Application NDA021130
FDAJun 9
Zyvox — ZYVOX
Application NDA021131
FDAJun 9
Zyvox — ZYVOX
Application NDA021132
FDAMay 8
Nurtec — NURTEC ODT
Application NDA212728
FDAMar 16
Nurtec — NURTEC ODT
Application NDA212728
FDAFeb 24
Braftovi — BRAFTOVI
Application NDA210496
FDAFeb 24
Braftovi — BRAFTOVI
Application NDA210496
FDAFeb 11
Paxlovid — PAXLOVID (COPACKAGED)
Application NDA217188
FDAFeb 11
Paxlovid — PAXLOVID (COPACKAGED)
Application NDA217188
FDAFeb 6
Idamycin — IDARUBICIN HYDROCHLORIDE, IDAMYCIN PFS
Application NDA050734
SECFeb 3
PFIZER INC (PFE) (CIK 0000078003)
Accession: 001-03619
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)